A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Data on the effectiveness of antipsychotics in the early phase of schizophrenia are limited. The authors examined the risk of rehospitalization and drug discontinuation in a nationwide cohort of 2,588 consecutive patients hospitalized for the first time with a diagnosis of schizophrenia between 2000 and 2007 in Finland. METHOD: The authors linked national databases of hospitalization, mortality, and antipsychotic prescriptions and computed hazard ratios, adjusting for the effects of sociodemographic and clinical variables, the temporal sequence of the antipsychotics used, and the choice of the initial antipsychotic for each patient. RESULTS: Of 2,588 patients, 1,507 (58.2%) collected a prescription for an antipsychotic during the first 30 days after hospital discharge, and 1,182 (45.7%, 95% confidence interval [CI]=43.7-47.6) continued their initial treatment for 30 days or longer. In a pairwise comparison between depot injections and their equivalent oral formulations, the risk of rehospitalization for patients receiving depot medications was about one-third of that for patients receiving oral medications (adjusted hazard ratio=0.36, 95% CI=0.17-0.75). Compared with oral risperidone, clozapine (adjusted hazard ratio=0.48, 95% CI=0.31-0.76) and olanzapine (adjusted hazard ratio=0.54, 95% CI=0.40-0.73) were each associated with a significantly lower rehospitalization risk. Use of any antipsychotic compared with no antipsychotic was associated with lower mortality (adjusted hazard ratio=0.45, 95% CI=0.31-0.67). CONCLUSIONS: In Finland, only a minority of patients adhere to their initial antipsychotic during the first 60 days after discharge from their first hospitalization for schizophrenia. Use of depot antipsychotics was associated with a significantly lower risk of rehospitalization than use of oral formulations of the same compounds. Among oral antipsychotics, clozapine and olanzapine were associated with more favorable outcomes. Use of any antipsychotic was associated with lower mortality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383 · cited 2×
“2% of patients did not regularly take medication as prescribed (8), that prescription completion rates ranged from 28% to 85% (9), and that irregular medication use rates ranged from 31% to 62% (9).”
BackgroundTiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Self-citationRobinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
Compliance With Medication Regimens for Mental and Physical Disorders
Cramer, J. A., & Rosenheck, R. (1998) · Psychiatric Services · doi:10.1176/ps.49.2.196 · Cited by 725
Adverse Effects of Atypical Antipsychotics: Differential Risk and Clinical Implications
Haddad, P. M., & Sharma, S. G. (2007) · CNS Drugs · doi:10.2165/00023210-200721110-00004 · Cited by 456
Self-citationMedication adherence of individuals with a first episode of psychosis
Coldham, E. L., Addington, J., & Addington, D. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.02437.x · Cited by 413
Research works printed but not linked: 4
- National Institute for Health and Clinical Excellence (NICE), 2009, Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update), Final Version (NICE Clinical Guideline 82)
- Young JL, 1986, Bull Am Acad Psychiatry Law, 14, 105
- Young JL, 1999, J Am Acad Psychiatry Law, 27, 426
- 10.1176/ps.2007.58.4.482 · doi:10.1176/ps.2007.58.4.482 · Paper page
Cited by
Items 401–500 of 618
Ting, E., Kamalvand, S., Shang, D., Siskind, D. J., & Kisely, S. R. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.12.004 · Cited by 6
Kraemer, S., Chartier, F., Augendre‐Ferrante, B., Psarra, V., Dyachkova, Y., Beselin, A., & Rouillon, F. (2012) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2224 · Cited by 8
Suzuki, H., Hibino, H., Inoue, Y., & Takaya, A. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.02.024 · Cited by 6
Comparison of Paliperidone Palmitate and Risperidone Long-Acting Injection in Schizophrenic Patients
Limosin, F., Belhadi, D., Comet, D., Pacou, M., Bouju, S., Impe, K. V., & Guillon, P. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000827 · Cited by 7
Pilon, D., Amos, T. B., Kamstra, R. L., Manceur, A. M., Khoury, A. C. E., & Lefèbvre, P. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1512477 · Cited by 7
Long-Acting Injectable versus Oral Antipsychotics for Restoration of Competency to Stand Trial.
Ghossoub, E., Minchin, S. A., Hayreh, D., & Newman, W. J. (2019) · PubMed · doi:10.29158/jaapl.003866-19 · Cited by 7
Alastanos, J. N., Paxos, C., & Emshoff, J. B. (2019) · Mental Health Clinician · doi:10.9740/mhc.2019.01.018 · Cited by 6
Physician Characteristics Associated With Prescription of Long-Acting Injectable Antipsychotics
Stip, É. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16lr11401 · Cited by 5
Faizi, A., McDermott, B. E., & Warburton, K. D. (2025) · CNS Spectrums · doi:10.1017/s1092852924002372 · Cited by 5
Choosing among the long-acting injectable antipsychotics: an evidence-based pragmatic guide
Citrome, L. (2025) · CNS Spectrums · doi:10.1017/s1092852925100400 · Cited by 10
Akindele, T., & Alwis, K. D. (2025) · Drugs - Real World Outcomes · doi:10.1007/s40801-025-00511-z · Cited by 7
Retrospective Review of Use of Adjunctive Psychostimulants in Patients with Schizophrenia
Zhand, N., Harvey, P. D., Osborne, R., Hatko, A., Stuyt, M., & Labelle, A. (2021) · Annals of Clinical Psychiatry · doi:10.12788/acp.0015 · Cited by 7
Odsbu, I., Hamina, A., Hjellvik, V., Handal, M., Haram, M., Tesli, M., Tanskanen, A. J., & Taipale, H. T. (2024) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13776 · Cited by 5
Liu, C.-H., Tsai, P.-H., & Chen, C. Y. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s154490 · Cited by 6
Li, N., Zhuo, J. M., Turkoz, I., Mathews, M., Feng, Y., & Tan, W. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1650022 · Cited by 6
Side-effect monitoring of continuing LAI antipsychotic medication in UK adult mental health services
Paton, C., Craig, T., McConnell, B., & Barnes, T. R. E. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125321991278 · Cited by 6
Martins, P. S., Caldas, F., Oliveira, C., Mota, J. C., & Gonçalves, M. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114581 · Cited by 8
Antipsychotics and Mortality in Adult and Geriatric Patients with Schizophrenia
Yeh, L., Lee, W., Kuo, K., & Pan, Y. (2023) · Pharmaceuticals · doi:10.3390/ph17010061 · Cited by 8
Kane, J. M., Rubio, J. M., Casciano, J. P., Dotiwala, Z., Hansen, R. T., III, Franzenburg, K. R., Philbin, M. J., & Thompson, S. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116455 · Cited by 7
Faries, D. E., Ascher‐Svanum, H., Phillips, G. A., Nyhuis, A. W., Sugihara, T., Stauffer, V. L., & Kinon, B. J. (2012) · BMC Medical Research Methodology · doi:10.1186/1471-2288-12-142 · Cited by 5
Holistic Consideration of Patients with Schizophrenia to Improve Medication Adherence and Outcomes
Lee, L.-T., Chen, K. C., Chang, W. H., Chen, P. S., Lee, I. H., & Yang, Y. K. (2015) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2015.13.2.138 · Cited by 8
Vauth, R., & Stieglitz, R. (2017) · Zeitschrift für Psychiatrie Psychologie und Psychotherapie · doi:10.1024/1661-4747/a000306 · Cited by 8
A comparison of depot and oral atypical antipsychotics in terms of metabolic syndrome markers
Aykut, D. S., & Karagüzel, E. Ö. (2017) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2017.1414575 · Cited by 7
Ji, P. Y., Menditto, A. A., Beck, N. C., Stuve, P., & Reynolds, J. R. (2018) · Community Mental Health Journal · doi:10.1007/s10597-018-0264-6 · Cited by 5
Espiridion, E. D., Lewandrowski, C., Shahriari, S., & Bestoyong, D. F. (2018) · Cureus · doi:10.7759/cureus.3775 · Cited by 5
Stip, É., Grignon, S., Roy, M., Bloom, D., Osman, O. T., Amiri, L., Aziz, K. A., Javaid, S. F., & Arnone, D. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1826930 · Cited by 5
Carmassi, C., Milani, F., Bertelloni, C. A., Massimetti, E., Cerù, A., & Dell’Osso, L. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13787 · Cited by 6
Şenay, O., Mursalova, Z., Gadimov, S., & Üçok, A. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000372 · Cited by 5
Park, S., Choi, M. Y., Choi, J., Park, E., Tchoe, H. J., Suh, J. K., Kim, Y. H., Won, S. H., Chung, Y., Bae, K., et al. (2018) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2018.16.1.361 · Cited by 5
Zhao, M., Qin, B., Mao, Y., Zhang, Y., Zhao, R., Wang, A., Wang, H., Zhao, J., & Wang, C. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s407259 · Cited by 7
Abdullah-Koolmees, H., Gardarsdóttir, H., Minnema, L. A., Elmi, K., Stoker, L. J., Vuyk, J., Goedhard, L. E., Egberts, T. C. G., & Heerdink, E. R. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125318762373 · Cited by 8
Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?
Pompili, M., Serafini, G., Innamorati, M., Ambrosi, E., Telesforo, L., Venturini, P., Giordano, G., Battuello, M., Lester, D., & Girardi, P. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.82 · Cited by 6
Adherence and Long-Acting Injectable Antipsychotics in Schizophrenia: An Update
Mohr, P., & Volavka, J. (2012) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.5350/dajpn20122504001 · Cited by 9
Editor’s Commentary: Additional Associate Editors, New Submission Category, and Meta-methodology
Turner, J. R. (2011) · Drug Information Journal · doi:10.1177/009286151104500402 · Cited by 5
beta-Lactam resistance and beta-lactamase isoforms of Moraxella catarrhalis isolates in Taiwan.
Fung, C.-P., Lee, S. C., Liu, P. Y., Jang, T. N., Wong, F. D., Kuo, B. I., Liu, C. Y., & Liu, Y. C. (1998) · PubMed · Cited by 5
The use of long-acting injectables in early-phase schizophrenia
Kane, J. M., Kishimoto, T., Achtyes, E. D., Rubio, J. M., & Correll, C. U. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00069-x · Cited by 5
Zhang, W., He, S., Wilson, L., Foix-Colonier, A., Pacou, M., Zhu, Y., Zhu, Y., Xue, L., Wang, Y., Li, J., et al. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s403252 · Cited by 4
Chiang, C. N., Chinen, M., Daskiran, M., Wakamatsu, A., & Turkoz, I. (2024) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12473 · Cited by 6
Antipsychotic use and unexpected death: a hospital-based case-control study
Mace, S., Dzahini, O., Cornelius, V. R., Anthony, D., Stewart, R. J., & Taylor, D. M. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12507 · Cited by 4
Suzuki, H., Hibino, H., Inoue, Y., & Takaya, A. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000533 · Cited by 4
Choice of antipsychotic to treat first-episode schizophrenia
Taylor, D. M. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30288-2 · Cited by 4
Okazaki, K., Yamamuro, K., & Kishimoto, T. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s148616 · Cited by 5
Wilson, M., Harris, M., Pereira, M., Buckle, J., Forshall, E., Murphy, T., Thompson, A. D., Kavanagh, G., & Whale, R. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.10.004 · Cited by 6
Pharmacological Strategies to Enhance Adherence in Schizophrenia
Hofer, A., & Fleischhacker, W. (2013) · Springer eBooks · doi:10.1007/978-88-470-2679-7_2 · Cited by 4
Wilson, M. R., Gutiérrez, B., Offord, S. J., Blanchette, C., Eramo, A., Earnshaw, S., & Kamat, S. (2016) · Drugs in Context · doi:10.7573/dic.212273 · Cited by 5
Kokurcan, A. (2019) · Nöro Psikiyatri Arşivi · doi:10.29399/npa.23548 · Cited by 4
Reducing long-term antipsychotic use: A therapeutic dead end?
Catts, S. V., & O’Toole, B. I. (2017) · The British Journal of Psychiatry · doi:10.1192/bjp.210.5.368 · Cited by 4
Leijala, J., Kampman, O., Gunnar, T., & Suvisaari, J. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116780 · Cited by 3
Correll, C. U., Rohner, H., Dimalta, S., Göldner, R. S., Assion, H., Langner-Timm, S., Sande, C. N., Rodríguez–Jiménez, R., Bioque, M., Gahr, M., et al. (2026) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2026.2628198 · Cited by 4
The Role of Long-Acting Injectable Antipsychotics in the Early Treatment of Schizophrenia
Harrison, S. J., Antunes, J., Knight, K., Johnston, K., Mehawej, J., Sanchez, P., & Correll, C. U. (2026) · CNS Drugs · doi:10.1007/s40263-026-01294-9 · Cited by 3
Tiihonen, J. (2011) · Evidence-Based Mental Health · doi:10.1136/ebmh.2011.100155 · Cited by 3
Self-citationSancho-Echeverria, R., Aymerich, C., Rodríguez-Sánchez, J. M., Gil, P., Pedruzo, B., Torres, M. Á. G., Fusar‐Poli, P., Arango, C., & Catalán, A. (2024) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253241243273 · Cited by 7
Updated rationale for the initial antipsychotic selection for patients with schizophrenia
Markota, M., Morgan, R. J., & Leung, J. G. (2024) · Schizophrenia · doi:10.1038/s41537-024-00492-y · Cited by 3
Lin, T.-C., Lin, C., & Chiu, H.-P. (2025) · Taiwanese Journal of Psychiatry · doi:10.4103/tpsy.tpsy_9_25 · Cited by 3
Throneberry, A. R., Burk, B. G., & Pruett, B. S. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1659290 · Cited by 5
Antipsychotika-Depotbehandlung im Wandel der Zeit
Knecht, G., Kuhn, J., Spittler, S., & Roll, S. (2016) · Nervenheilkunde · doi:10.1055/s-0037-1616350 · Cited by 3
Schmidt-Kraepelin, C., Engelke, C., Kahl, K. G., & Cordes, J. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000957 · Cited by 3
Papakostas, S., Dar, A., & Ratna, L. (2020) · Psychiatric Quarterly · doi:10.1007/s11126-020-09756-z · Cited by 5
Pippal, N., Halder, S., Srivastava, S., Kar, R., Gupta, R., & Almeida, E. A. (2021) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2021.1994613 · Cited by 3
Recovery-Oriented Psychopharmacological Interventions in Schizophrenia
Mallet, J., Strat, Y. L., Dubertret, C., & Gorwood, P. A. P. M. (2022) · Comprehensive approach to psychiatry · doi:10.1007/978-3-030-98301-7_9 · Cited by 4
Une approche de la psychopharmacologie des premiers épisodes psychotiques axée sur le rétablissement
Béchard, L., Corbeil, O., Malenfant, E., Lehoux, C., Stip, É., Roy, M., & Demers, M. (2021) · Santé mentale au Québec · doi:10.7202/1088180ar · Cited by 5
Ferrara, M., Zaffarami, G., Simonelli, G., Domenicano, I., Vecchioni, L., Toffanin, T., Folesani, F., Zotos, S., Scrignoli, C., Bertelli, R., et al. (2024) · Early Intervention in Psychiatry · doi:10.1111/eip.13513 · Cited by 3
Gao, Y. N., Wang, R., Gu, G., Chung, R., & Olfson, M. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.03.034 · Cited by 3
Pharmacotherapeutic Strategies to Prevent Relapse in Schizophrenia
Kim, J. H., Piao, Y. H., Shen, Q., & Chung, Y. (2018) · 신경정신의학 · doi:10.4306/jknpa.2018.57.3.225 · Cited by 3
Nikolić, N., Hill, K., Campbell, E., Wickramasinghe, V., & Whale, R. (2020) · Early Intervention in Psychiatry · doi:10.1111/eip.12962 · Cited by 4
Sīle, L., Bezina, K., Kvartalovs, D., Erts, R., Kikuste, S., Šapele, I., & Rancāns, E. (2020) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2020.1799429 · Cited by 3
Validation of an economic model of paliperidone palmitate for chronic schizophrenia
Einarson, T. R., & Hemels, M. E. H. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.838571 · Cited by 3
Zhao, Y., Kishi, T., Iwata, N., & Ikeda, M. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s52317 · Cited by 3
Singh, S., Haddad, P., Husain, N., Heaney, E., Tomenson, B., & Chaudhry, I. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316632458 · Cited by 3
Self-citationPaliperidone Palmitate Treatment in Outpatient Care Setting: A Naturalistic Study.
Lorenzo, R. D., Cameli, M., Bolondi, M., Landi, G., Moretti, V., Piemonte, C., & Pollutri, G. (2016) · Psychopharmacology bulletin · doi:10.64719/pb.4341 · Cited by 3
Zaniolo, O., Ghetti, G., Povero, M., & Pradelli, L. (2019) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v20i1.1393 · Cited by 3
Cai, Q., Patel, C. A., Kim, E., Connolly, N., Tunceli, O., & Khoury, A. C. E. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00913-w · Cited by 5
Taipale, H. T., Rahman, S. G., Tanskanen, A. J., Mehtälä, J., Hoti, F. J., Jedenius, E., Enkusson, D., Levál, A., Sermon, J., Tiihonen, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-58078-4 · Cited by 3
Self-citationBenelmokhtar, J. M., Chiliza, B., Phahladira, L., Emsley, R. A., & Asmal, L. (2021) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v27i0.1657 · Cited by 4
Psychopharmakotherapie – klinisch-empirische Grundlagen
Volz, H., Kasper, S. F., & Möller, H. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_31 · Cited by 3
Miyamoto, S., Merrill, D. B., Jarskog, L. F., Fleishhacker, W. W., Marder, S. R., & Lieberman, J. A. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch104 · Cited by 5
Dıkeç, G., Brown, E., Bressington, D. T., Thompson, A. D., & Gray, R. J. (2022) · Healthcare · doi:10.3390/healthcare10091732 · Cited by 4
Fountoulakis, K. Ν., Karakatsoulis, G. N., Abraham, S., Adorjan, K., Ahmed, H. U., Alarcón, R. D., Arai, K., Salihu, A., Berk, M., Levaj, S., et al. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116459 · Cited by 9
Vieta, E., Montejo, Á., Pillinger, T., Dell’Osso, B. M., Dimitraka, M., Farooq, S., Jesús, G., Parro-Torres, C., Wobrock, T., & Pappa, S. (2025) · Annals of General Psychiatry · doi:10.1186/s12991-025-00620-7 · Cited by 2
Krebs, J. (2026) · Forensische Psychiatrie Psychologie Kriminologie · doi:10.1007/s11757-026-00938-2 · Cited by 2
Twumasi, R., Gronemann, F. H., Hjorthøj, C. R., Howes, O. D., Lange, M., Nordentoft, M., & Osler, M. (2026) · Psychological Medicine · doi:10.1017/s0033291726104693 · Cited by 2
Tourian, L., & Margolese, H. C. (2013) · Neuropsychiatry · doi:10.2217/npy.13.7 · Cited by 2
Strategies for optimizing medication adherence in schizophrenia
Morrissette, D. A., & Cutler, A. J. (2012) · CNS Spectrums · doi:10.1017/s1092852912000405 · Cited by 2
Grover, S., Singla, H., Chakrabarti, S., & Avasthi, A. (2019) · Indian Journal of Psychological Medicine · doi:10.4103/ijpsym.ijpsym_269_19 · Cited by 3
Performance in Practice: Practice Assessment Tool for the Care of Patients With Schizophrenia
Fochtmann, L. J., Medicus, J., & Hong, S.-H. (2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20200034 · Cited by 3
Stress, Vulnerability, and Suicide: The Stress–Diathesis Model
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.003 · Cited by 3
Long-acting drug delivery systems for schizophrenia treatment
Sreeraj, V. S., Shivakumar, V., Rao, N. P., & Venkatasubramanian, G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821749-8.00009-4 · Cited by 3
Kim, G., Rim, S. J., Jo, M., Lee, M. G., Park, S. J., & Park, S. (2022) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2022.20.3.573 · Cited by 2
Khomova, N., & Ташпулатова, Ф. К. (2018) · Avicenna Bulletin · doi:10.25005/2074-0581-2018-20-2-3-299-304 · Cited by 2
Berger, S. J., & Hofer, A. (2023) · Neuropsychiatrie · doi:10.1007/s40211-023-00474-z · Cited by 4
Schizophrenia Management Approaches: A Look at Progress and Challenges
Patel, K. P., & Oroszi, T. L. (2025) · World Journal of Neuroscience · doi:10.4236/wjns.2025.151003 · Cited by 2
Alharthi, M. A., Al-Raddadi, R. M., & Alfakeh, S. A. (2025) · Brain and Behavior · doi:10.1002/brb3.70807 · Cited by 1
Budget Impact Analyse von Paliperidon Palmitat im österreichischen Versorgungskontext
Ransmayr, S., Mehnert, A., & Mahlich, J. (2013) · PharmacoEconomics German Research Articles · doi:10.1007/s40275-013-0003-0 · Cited by 2
Abdel‐Baki, A., Poulin, É., Medrano, S., Padilha, P. P. D. O., Stip, É., & Potvin, S. (2022) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2022.2079531 · Cited by 2
Progress in compliance research and intervention: a commentary
Rosenheck, R. A. (2013) · World Psychiatry · doi:10.1002/wps.20062 · Cited by 2
Bruk av antipsykotiske depotinjeksjoner
Høiseth, G., & Bentsen, H. (2012) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.11.0721 · Cited by 2
The use of long-acting injectable antipsychotic medication
Mutsatsa, S. H. (2017) · British Journal of Mental Health Nursing · doi:10.12968/bjmh.2017.6.3.114 · Cited by 2
Schizophrenie: Überblick zu einer der schwerstwiegenden psychiatrischen Erkrankungen
Lammer, E., Klingelhöfer, D., Bendels, M. H. K., Ohlendorf, D., Groneberg, D. A., & Spallek, M. (2018) · Zentralblatt für Arbeitsmedizin Arbeitsschutz und Ergonomie · doi:10.1007/s40664-018-0274-9 · Cited by 2
The Long-Acting Injectable Antipsychotics in Clinical Practice
Lee, K. Y. (2019) · 신경정신의학 · doi:10.4306/jknpa.2019.58.1.29 · Cited by 2
Janzen, D., Bolton, J. M., Leong, C., Kuo, I. F., & Alessi‐Severini, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.879224 · Cited by 4
Metadata
- Authors
- Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P.
- Affiliations
- NHS Lothian (GB)
- Venue
- American Journal of Psychiatry
- Published
- 2011-06
- Volume
- 168
- Issue
- 6
- Pages
- 603-609
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2160096204
- Cited by
- 619
- References
- 28
- Citations by year
- 2026: 21 · 2025: 30 · 2024: 21 · 2023: 35 · 2022: 38 · 2021: 41 · 2020: 32 · 2019: 42 · 2018: 51 · 2017: 55 · 2016: 39 · 2015: 52 · 2014: 42 · 2013: 61 · 2012: 44
- FWCI
- 34.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- schizophrenia, antipsychotic drugs, long-acting injectable antipsychotics, oral antipsychotics, hospital readmission, treatment discontinuation, clozapine, olanzapine, risperidone, mortality, medication adherence, first hospitalization
- MeSH terms
- Administration, Oral, Adolescent, Adult, Delayed-Action Preparations, Drug Implants, Finland, Hospitalization, Humans, Injections, Middle Aged, Patient Readmission, Schizophrenia, Antipsychotic Agents, Cohort Studies, Treatment Outcome, Secondary Prevention, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.